CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with PNH.
A separate study found that Soliris was observed to reduce indicators of pulmonary artery hypertension (PAH) in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a new analysis of clinical trial data. Both sets of data were presented in oral sessions yesterday at the 50th Annual Meeting of the American Society of Hematology.
"The common, severe and progressive clinical consequences of PNH are becoming more apparent as researchers gain more experience and basic knowledge with regard to this disease," said Leonard Bell, M.D., Chief Executive Officer of Alexion.
Blood Markers of Thrombin Generation and Inflammation
Research titled "Eculizumab Therapy Results in Rapid and Sustained
Decreases in Markers of Thrombin Generation and Inflammation in Patients with
PNH" was presented yesterday in an oral session at the ASH annual meeting by
Ilene Ceil Weitz, M.D., Assistant Clinical Professor of Medicine, Jane Anne
Nohl Division of Hematology, Keck School of Medicine of the
Recently published research showed that patients with PNH were observed to
have 92 percent fewer blood clots (thromboses) during treatment with Soliris
(1) compared to the period of time prior to Soliris treatment. To better
understand the mechanism for this observed reduction, researchers used highly
sensitive laboratory tests to track levels of blood markers in order to
determine the effect of Soliris on markers of thrombin generation and
inflammation among ei
|SOURCE Alexion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved